From Cancer Communicator
News & Analysis
Conference coverage, FDA updates, clinical trial analysis, and more.
-
Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (RASolute3o2)
ASCO Annual Meeting 2026 RASolute 302 Daraxonrasib versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. Phase 3, open-label, randomized. Total N 500 248…
-
QuickView: Abemaciclib vs Placebo in Advanced Dedifferentiated Liposarcoma (SARC041)
ASCO 2026 Annual Meeting · Plenary SARC041 Abemaciclib versus placebo in advanced dedifferentiated liposarcoma. A phase 3 randomized, double-blind trial. 108Total randomized PFSPrimary end…
-
QuickView: Sunvozertinib vs Chemotherapy in Advanced NSCLC with EGFR Exon 20 Insertion (WU-KONG28)
First-line sunvozertinib prolongs PFS in EGFR exon 20 insertion–mutated advanced NSCLC
-
#ASCO26 News: Teclistamab Monotherapy Improves PFS and OS in Early RRMM
Results from the phase 3 MajesTEC-9 trial, presented on Day 1 of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that…
-
#ASCO26: First-Line Sunvozertinib Prolongs PFS in EGFR Exon 20 Insertion–Mutated Advanced NSCLC
The oral EGFR tyrosine kinase inhibitor sunvozertinib significantly improved progression-free survival (PFS) compared with carboplatin–pemetrexed as first-line treatment for advanced nonsquamous non–small cell lung…
-
FDA Approves Pivekimab Sunirine for BPDCN
On May 27, 2026, the U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz), a CD123-directed antibody-drug conjugate delivering a DNA alkylating payload,…
-
Aspiring doctors may need to find another quarter million dollars to go to school
Workforce access · Federal student loan reform Aspiring doctors may need to find another quarter million dollars to go to school. The federal funding…
-
ASCO GU 2026: Perioperative EV/Pembrolizumab Outperforms Gemcitabine/Cisplatin in MIBC
At the 2026 ASCO Genitourinary Cancers Symposium, Matthew D. Galsky, MD, presented results from the phase 3 KEYNOTE-B15 study showing that perioperative enfortumab vedotin…
-
ASCO GI 2026: Encorafenib/Cetuximab Plus FOLFIRI Improves Response in BRAF V600E CRC
At the 2026 Gastrointestinal Cancers Symposium, BREAKWATER Cohort 3 delivered the clearest signal yet that encorafenib plus cetuximab can be paired with FOLFIRI (folinic…
-
FDA Closes Out 2025 With 16 Oncology Approvals in Six Weeks
The US Food and Drug Administration (FDA) closed out 2025 with 16 hematology/oncology approvals in just six weeks, marking one of the most active…
-
Oral Menin-Based Triplet Shows Strong Early Activity in ND AML
The phase II SAVE trial presented at the 2025 American Society of Hematology (ASH) Annual Meeting (Abstract 47) delivered early but compelling results from…
-
FDA Approves Liso-Cel for R/R MZL
On December 4, 2025, the US Food and Drug Administration (FDA) approved the CD19/CD3-directed CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with…